Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ibudilast for prevention of oxaliplatin-induced neurotoxicity in metastatic colorectal cancer
ACTRN12619000566134Phase 2Recruiting
- Sponsor
- Australasian Gastro-Intestinal Trials Group
- Start
- Jan 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of ibudilast in peripheral neuropathy (CIPN) and oxaliplatin-induced polyneuropathy (OXIPN), sponsored by Australasian Gastro-Intestinal Trials Group. Primary endpoint: Acute neurotoxicity. Started Jan 2021; status: recruiting.
02
Drugs
ibudilast
03
Conditions
peripheral neuropathy (CIPN)oxaliplatin-induced polyneuropathy (OXIPN)
Beyond the preview
Go deeper on ACTRN12619000566134.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12619000566134.